Efficacy and Mechanism of *Mallotus furetianus* Müll. Arg. Extract on Nonalcoholic Fatty Liver Disease

Daobin Lin, Yi Ding, Yabo Cheng, Yubin Chen, Yunting Tang, Xiaowen Wu, and Yawei Cheng

1Department of Cardiology, Hainan Provincial Hospital of Traditional Chinese Medicine, Haikou 570293, China
2Department of Disease Prevention, Hainan Provincial Hospital of Traditional Chinese Medicine, Haikou 570293, China
3Department of Wrist, Sichuan Orthopedic Hospital, Chengdu 610041, China
4Department of Disease Prevention, Hainan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Chinese Medicine, Haikou 570100, China

Correspondence should be addressed to Yawei Cheng; chengyawei1990@outlook.com

Received 21 December 2021; Revised 11 March 2022; Accepted 5 April 2022; Published 28 April 2022

Academic Editor: Ruchika Garg

Copyright © 2022 Daobin Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nonalcoholic fatty liver disease (NAFLD) is currently the major cause of chronic liver disease globally. To observe the sedative effect of *Mallotus furetianus* extract (MFE) on NAFLD and the potential molecular mechanism, a high-fat diet (HFD) was used to induce NAFLD in rats for 8 weeks. Rats were orally given MFE (1.7 g/kg, 2.5 g/kg, and 3.3 g/kg) every day. Serum and liver biochemical indexes were detected. 16S rDNA sequencing was performed to test the changes in the gut microbiota. Mass spectrometry was used to analyze the changes in blood and liver metabolites and to perform a joint analysis of differential flora and differential metabolites. The results showed that MFE alleviated liver injury and decreased hepatic lipids content. ELISA analysis certified that MFE reduced inflammation levels in rats fed with HFD. Compared to HFD rats with a normal diet, MFE significantly changed the overall structure of the intestinal flora and the composition of the intestinal microbes destroyed by HFD. In addition, MFE changes the metabolic levels of lipids and proteins in HFD rats. In conclusion, MFE effectively treated NAFLD and significantly improved the overall structure and intestinal microbial composition of the intestinal microbiota. The abundance of *Bacteroides fragilis* and *Escherichia coli* increased significantly in the partridge tea treatment group.

1. Introduction

NAFLD has now become an important cause of chronic liver disease in developed countries. The prevalence of NAFLD in adult people is 10% to 30%, of which 10% to 20% are nonalcoholic steatohepatitis (NASH). The incidence of liver cirrhosis is as high as 25% within 10 years [1, 2]. NAFLD covers many disease states, such as fatty liver, nonalcoholic steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Various levels of metabolic factors such as insulin resistance, dyslipidemia, and inflammation are increasingly regarded as the main pathogenic factors leading to liver steatosis, but the specific pathogenesis of NAFLD is complex and unclear [3, 4]. In addition, there is currently no approved treatment for NAFLD, so new treatments to treat this complex liver disease are urgently needed [3, 4].

*Mallotus furetianus* is an economic plant from Hainan Island in China. Its leaves are used as an aromatic beverage and as a folk remedy for the treatment of cholecystitis [5]. The extract also has antioxidant and antiatherosclerotic activities. The water extract can reduce intracellular lipid accumulation in oleic acid-induced fat degeneration of liver cancer cells [5]. These results indicate that MF is effective in treating liver steatosis.

The intestinal flora has an important regulatory effect on NAFLD. The intestinal flora could affect the intestinal permeability, the luminal metabolism of cholecytic acid, lipoprotein lipase, endogenous alcohol, and toxic
compounds [6, 7]. Increased intestinal permeability and lipoprotein lipase production in intestinal diseases contribute to the pathogenesis of NAFLD. The gut microbiota, which affects bile cholic acid biosynthesis in the course of NAFLD by regulating the liver-like protein X receptor (FXR) and HF-induced liver steatosis, inhibits the gut by changing the gut microbiota [8, 9]. The fermentation of short-chain fatty acids and carbohydrates produced by intestinal microorganisms helps to inhibit fat synthesis and accelerate the oxidation of fat in the liver. Some enzymes produced by gut microbes convert choline in food into toxic compounds, which are then absorbed by the liver, leading to liver damage and inflammation. In addition, the intestinal flora is the primary source of endogenous alcohol, and in patients with NASH. Large numbers of bacteria have been reported to produce alcohol [10–12]. Treatment with probiotics or prebiotics to relieve NAFLD is effective, further confirming the influence of intestinal flora on NAFLD. Therefore, regulating the intestinal flora is a potential treatment for NAFLD. In this study, HFD was used to induce NAFLD in rats, and 16S rDNA sequencing and metabolomics were used to analyze the regulatory effect and molecular mechanism of MFE on NAFLD.

2. Materials and Methods

2.1. Experimental Animals. Fifty male Wistar rats (200–250 g, 4–6 weeks old) were obtained from the Shanghai Laboratory Animal Center of Chinese Academy of Sciences (Shanghai, China). The animals were fed with standard laboratory feed and allowed to drink tap water at will. All animals were appropriately treated in accordance with the institutional animal care guidelines approved by the Experimental Animal Ethical Committee of Hainan Provincial Hospital of Traditional Chinese Medicine (IACUC-20200112-02).

2.2. Treatment of Rats. Fifty rats were divided into 5 groups randomly: normal-chow diet (NCD) \((n = 10)\); HFD \((n = 10)\); HFD + MFE \((1.7 \text{ g/kg})\) \((n = 10)\); HFD + MFE \((2.5 \text{ g/kg})\) \((n = 10)\); and HFD + MFE \((3.3 \text{ g/kg})\) \((n = 10)\). MFE is dissolved in physiological saline solution. The rats were fed HFD, and MFE was administered daily for 8 weeks.

2.3. Analysis of Serum ALT/AST Activities. The blood sample was stored at 4°C for 2 hours and then centrifuged at 860 xg for 15 minutes before serum collection. The kit was used to measure serum ALT and AST according to the manufacturer’s instructions [10–12].

2.4. Assessment of IL-1β, IL-6, TNFα, and ADS/LEP. For each rat, commercial ELISA kits were utilized to quantify the level of serum tumor inflammatory factors (IL-1β, IL-6, and TNFα) and serum ADS/LEP, in accordance with the manufacturer’s instructions [13].

2.5. Liver Histological Evaluation. Liver sections were fixed in 10% formalin solution for 24 hours and then embedded in paraffin. The specimen sections \((5 \mu m)\) were stained with hematoxylin-eosin (H&E) to observe the histology of liver damage. Oil red O staining was performed to observe the accumulation of lipids in the liver [14].

2.6. DNA Extraction, PCR Amplification, and MiSeq Sequencing. Samples were stored at −80°C until the DNA is extracted. QIAamp DNA Stool Mini Ki was used to extract
FIGURE 2: MFE reduced liver injury in rats fed with HFD, with 10 rats in each group. (a) Detection of serum ALT activity. (b) Detection of serum AST activity. (c) Detection of serum GGT activity (n = 10). (d) Liver H&E staining. Magnification, 200 times. (I) NCD, (II) HFD, (III) HFD + MFE (1.7 g/kg), (IV) HFD + MFE (2.5 g/kg), and (V) HFD + MFE (3.3 g/kg). Data were expressed as mean ± SEM. *P < 0.05, **P < 0.01.
all genomic DNA from each sample. As mentioned earlier, PCR amplification and MiSeq sequencing were performed. In summary, Phusion High-Fidelity PCR Master Mix and HF buffer (New England Biolabs, UK) were used to amplify the V4-V5 region of the bacterial 16S rDNA. Barcode index PCR primers 515F and 926R were used. The amplicon library with the AXYGEN AxyPrep DNA Gel Extraction Kit (AXYGEN Scientific, Union City, CA, USA) was purified, normalized with FTC-3000™ Real-Time PCR, using the MiSeq instrument (Illumina), using 2 × 300 cycles of V3 reagents. The cassette is sequenced.

2.7. Bioinformatics Analysis. The original sequencing reads were optimized, and bioinformatics analysis was performed. Simply put, the original data are demultiplexed according to the barcode. Trimmatic (version 0.35) was used to eliminate poor-quality base pairs. FLASH (version 1.2.11) and mothur (version 1.33.3) were used to merge and filter the truncated reads. The multivariate statistical analysis was carried out with mothur, UPARSE (USEARCH version v8.1.1756), and R (version 3.2.3). The clean labels are aggregated in OTU and then assigned to the corresponding taxon according to the Silva 119 database. The multifactor analysis was performed to assess the total structural changes in the intestinal flora, and the sparse curve and alpha diversity were tested to assess the richness and diversity of each group of intestinal flora. The main coordinate analysis (PCoA) was performed based on the UniFrac distance and the UniFrac tree. mothur and R were used to analysis of α-diversity and β-diversity [15].

2.8. Metabolomic Analysis. A liquid chromatography (LC) quadrupole mass spectrometry (MS) amino acid analysis system with two independent liquid phase time-of-flight (LC-time) mass spectrometry platforms was used to measure the level of metabolites in the serum. For liver samples, the above 3 LC-MS platforms were analyzed by methanol/water extraction.

2.9. Statistical Analysis. Data are expressed as mean ± standard error of mean (SEM). Significant differences were determined by one-way analysis of variance (one-way ANOVA) and LSD post test. \( P < 0.05 \) was considered statistically significant.
3. Results

3.1. MFE Does Not Affect Weight in Rats Fed with HFD.
After pathological examination confirmed that the model was successfully established, rats were given 1.7g/(kg·d), 2.5g/(kg·d), and 3.3g/(kg·d) partridge tea solution by intragastric administration, and the normal group and the model group were given 10ml/(kg·d) body weight distilled water orally. The administration period was 4 weeks, during which all rats were fed with basic feed and free drinking water, and weighed once a week. Figure 1(a) shows the body weight curve from 0 to 12 weeks after treatment. No significant differences were found between the groups. Figure 1(b) is the change in overall body weight within 12 weeks. It can be said that MFE has no effect on weight gain from a high-fat diet.

3.2. MFE Reduced Liver Injury in Rats Fed with HFD. As shown in Figures 2(a)–2(c), MFE (1.7, 2.5, and 3.3 g/kg) reduced the increased serum ALT, AST, and GGT activities induced by HFD in rats. Moreover, the effect of MFE (3.3 g/kg) was better than the other two doses. The liver H&E staining results indicated that MFE could reduce HFD-induced liver steatosis in rats (Figure 2(d)).

3.3. MFE Reduced Hepatic Lipids Accumulation in Rats Fed with HFD. The results showed that MFE (1.7, 2.5, and 3.3 g/kg) reduced the increased contents of serum TC, TG, LDL-C, and HDL-C induced by HFD in rats. In addition, the effect of 3.3 g/kg MFE was better than the other dose (Figure 3).

3.4. MFE Reduced Inflammation Levels in Rats Fed with HFD. Next, the expression of inflammation factors was detected in rats. The results showed that MFE (1.7, 2.5, and 3.3 g/kg) reduced the increased contents of serum IL-1β, IL-6, TNFa, LEP, and ADP induced by HFD in rats (Figure 4). Moreover, the effect of 3.3 g/kg MFE was better than the other dose.

3.5. MFE Changed the Composition of the Gut Microbiota. 16S rDNA sequencing generated 593,121 high-quality sequences and 1,625 OTUs from 30 stool samples. Wien image analysis showed that the overall microbial diversity between the three groups was significantly different (Figure 5(a)). The dilution curve shows that the depth of the current sequence is sufficient and OTU is common (Figure 5(b)). According to the weighted and unweighted table of PCoA results, compared with the control group, the structure of the intestinal flora of the HFD group with the second major component (PC2) changed, and these changes were reversed after high-dose MFE administration (Figures 5(c) and 5(d)). Weighted and unweighted UniFrac trees show three different microbial communities in each group (Figures 5(e) and 5(f)).
NCD NAFLD

MFE

(a)

PCoA – PC1 vs PC2

(b)

PCoA – PC1 vs PC2

(c)

PC1 (43.65%)

(d)

PC1 (25.97%)

Figure 5: Continued.
Figure 5: α-Diversity analysis and structural changes of the gut microbiota. (a) Venn picture of multiple samples. (b) Rarefaction curves. (c) Weighted table of PCoA results. (d) Unweighted table of PCoA results. (e) Weighted UniFrac trees. (f) Unweighted UniFrac trees.
Cladogram

(a) Evidence-Based Complementary and Alternative Medicine

(b) Figure 6: Continued.
Figure 6: Continued.
In addition, LEfS was performed to analyze the statistical differences between the three groups. In the clade diagram, the circles radiating from the inside to the outside indicate the order level from the strain to the genus (or species). Each small circle of different degrees represented a level of the level, and the diameter of the small circle was proportional to the relative frequency. Species without a significant difference were colored yellow and biomarkers of different species were colored according to the group. The red knot represented the microbiome that plays an important role in the MFE group, and the green knot represented the microbiome that plays an important role in the MFE high-dose group. The blue knot represented the microbial taxa that play an important role in the NAFLD group (Figure 6(a)).

The LDA value distribution histogram showed species with an LDA score greater than 4, showing species with...
significant differences in abundance in different groups, and the length of the histogram represented the impact of different species (Figure 6(b)). Further analysis of the relative abundance of the biomarker in each group of samples found that *Bacteroides fragilis* and *Escherichia coli* in the NCD group were significantly higher than those in the other two groups, *Staphylococcus xylosus* in the MFE group was significantly higher than that in the other two groups, and *Ruminococcus flavefaciens* in the NAFLD group was significantly higher than the other two groups (Figure 6(c)). In addition, we combined the 16S flora analysis data with the metabolome. We found that the abundance of *Bacteroides* was negatively correlated with the contents of 3R, 6’Z)-3,4-dihydro-8-hydroxy-3-(6-pentadecenyl)-1H-2-benzopyran-1-one, 4,5-dihydropriperlongumine, 8-hydroxyprinosinol 4-glucoside, cytidine, hypoxanthine, isoniazid alpha-ketoglutaric acid, L-isoleucine, and prolyl-alanine, and positively correlated with the contents of taurochenodesoxycholic acid, p-aminobenzoic acid, and marmesin rhamnoside (Figure 6(d)).

### 4. Discussion

In recent years, NAFLD has become more and more common in the world, which has attracted widespread attention from researchers and doctors [16]. Studies have shown that a variety of Chinese herbal medicines and natural active ingredients extract have good therapeutic prospects for NAFLD [17–19]. These studies provide new ideas for the treatment of NAFLD to find effective drugs from traditional Chinese medicine. MFE has a lipid-lowering effect and is widely used in the treatment of NAFLD [20]. MFE has a lipid-lowering effect on the blood and liver of rats with HFD fed [5]. HFD is widely used to induce experimental NAFLD in mice, and its pathology is very similar to human NAFLD [21]. In this study, liver TG, CT levels, and liver histopathology and staining showed that MFE reduced liver lipid accumulation in high-fat diet rats. These results further confirmed the protective effect of MFE on NAFLD and proved the great potential of MFE in the clinical treatment of NAFLD.

Elevated serum ALT and AST activities are usually signs of liver cell damage. Liver cell damage was related to the occurrence of NAFLD [22]. The results indicated that MFE also reduced the increased ALT/AST activity in the serum of HFD-fed rats, suggesting that it has a protective effect on liver cell damage during the progression of NAFLD. To determine the causes of weight loss and anti-inflammatory effects, we analyzed the gut microbiota of rats. The α-diversity analysis showed that the microbial accumulation of liaraglutide in NAFLD rats was significantly reduced and not reversed. The β-diversity analysis shows that liaraglutide has a significant influence on the composition of the intestinal flora. Hence, we speculate that liaraglutide may have received a healthier composition of the intestinal flora, that is beneficial for lipid metabolism and inhibits inflammation.

Previous studies have shown that *Phascolarctobacterium*, *Blautia*, *Ruminococcus*, *Clostridium*, etc., in the samples of the NAFLD group are significantly increased, and they all have the ability to ferment to produce short-chain fatty acids (SCFAs) in the human intestine. Studies have shown that NAFLD affects the intestinal SCFA content. The level of SCFAs detected in the feces of NAFLD patients is increased, and the concentration of SCFAs produced by bacterial fermentation is relatively higher, suggesting a more adequate energy intake. The content of *Lachnospiraceae* in the NAFLD group was significantly reduced. *Lachnospiraceae* is a butyrate-producing bacteria. Its reduced content can significantly reduce the content of butyrate in SCFAs. Butyrate can be used as an important energy source for colon cells and also participates in inhibiting inflammation and enhanced screen long function. These indicate that the concentration of SCFAs in the intestinal tract of NAFLD is increased, which may only be due to the increase in the content of some of them, such as acetic acid [23]. We combined the 16S flora analysis data with the metabolome and found that the contents of 3R, 6’Z)-3,4-dihydro-8-hydroxy-3-(6-pentadecenyl)-1H-2-benzopyran-1-one, 4,5-dihydropriperlongumine, 8-hydroxyprinosinol 4-glucoside, cytidine, hypoxanthine, isoniazid alpha-ketoglutaric acid, L-isoleucine, prolyl-alanine, taurochenodesoxycholic acid, p-aminobenzoic acid, and marmesin rhamnoside were correlated with the flora in the NAFLD group. This study is consistent with previous studies, showing that the intestinal flora can regulate metabolic pathways and participate in regulating the life activities of the body.

### 5. Conclusion

MFE reduced liver damage and lipid accumulation in NAFLD rats. MFE significantly improved the overall structure and intestinal microbial composition of the intestinal microbiota. The abundance of *Bacteroides fragilis* and *Escherichia coli* increased significantly in the MFE treatment group. In future research, we will further clarify the molecular regulation mechanism and target of MFE based on molecular docking, affinity chromatography, and coprecipitation experiments and lay a better research foundation for the clinical application of MFE.

### Data Availability

The data used to support this research are included within this manuscript.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### Acknowledgments

This research was supported by the Hainan Provincial Basic and Applied Basic Research Program (Natural Science Field) High-Level Talent Project (2019RC383).
References

[1] M. S. Mundi, S. Velapati, J. Patel, T. A. Kellogg, B. K. Abu Dayeh, and R. T. Hurt, "Evolution of NAFLD and its management," *Nutrition in Clinical Practice*, vol. 35, no. 1, pp. 72–94, 2020.

[2] A. A. Kolodziejczyk, D. Zheng, O. Shibolet, and E. Elinav, "The role of the microbiome in NAFLD and NASH," *EMBO Molecular Medicine*, vol. 11, no. 2, 2019.

[3] M. Meroni, M. Longo, A. Rustichelli, and P. Dongiovanni, "Nutrition and genetics in NAFLD: the perfect binomial," *International Journal of Molecular Sciences*, vol. 21, no. 8, p. 2986, 2020.

[4] M. Gjorgjieva, C. Sobolewski, D. Dolicka, M. Correia de Sousa, and M. Foti, "miRNAs and NAFLD: from pathophysiology to therapy," *Gut*, vol. 68, no. 11, pp. 2065–2079, 2019.

[5] E. Yoshikawa, I. Matsui-Yuasa, X. Huang, Y. Kobayashi, and A. Kojima-Yuasa, "Mallotus furetianus extract protects against ethanol-induced liver injury via the activation of the cAMP-PKA pathway," *Food Sciences and Nutrition*, vol. 8, no. 7, pp. 3936–3946, 2020.

[6] J. Chen and L. Vitetta, "Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications," *International Journal of Molecular Sciences*, vol. 21, no. 15, p. 5214, 2020.

[7] J. Aron-Wisnewsky, C. Vigliotti, J. Witjes et al., "Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders," *Nature Reviews Gastroenterology & Hepatology*, vol. 17, no. 5, pp. 279–297, 2020.

[8] A. P´erez-Montes de Oca, M. T. Julian, A. Ramos, M. Puig-Domingo, and N. Alonso, "Microbiota, fiber, and NAFLD: is there any connection?" *Nutrients*, vol. 12, no. 10, p. 3100, 2020.

[9] E. E. Canfora, R. C. R. Meex, K. Venema, and E. E. Blaak, "Gut microbial metabolites in obesity, NAFLD and T2DM," *Nature Reviews Endocrinology*, vol. 15, no. 5, pp. 261–273, 2019.

[10] Y. Ji, Y. Yin, L. Sun, and W. Zhang, "The molecular and mechanistic insights based on gut-liver Axis: nutritional target for non-alcoholic fatty liver disease (NAFLD) improvement," *International Journal of Molecular Sciences*, vol. 21, no. 9, p. 3066, 2020.

[11] G. Svegliati-Baroni, B. Patricio, G. Lioci, M. P. Macedo, and A. Gastaldelli, "Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH," *International Journal of Molecular Sciences*, vol. 21, no. 16, p. 5820, 2020.

[12] J. Henao-Mejia, E. Elinav, C. Jin et al., "Inflammosome-mediated dysbiosis regulates progression of NAFLD and obesity," *Nature*, vol. 482, no. 7384, pp. 179–185, 2012.

[13] F. Zhang, L. Wang, J. J. Wang, P. f. Luo, X. t. Wang, and Z. f. Xia, "The caspase-1 inhibitor AC-YVAD-CMK attenuates acute gastric injury in mice: involvement of silencing NLRP3 inflammasome activities," *Scientific Reports*, vol. 6, no. 1, p. 9466, 2016.

[14] X. Gao, S. Guo, S. Zhang, A. Liu, L. Shi, and Y. Zhang, "Correction to: matrine attenuates endoplasmic reticulum stress and mitochondrion dysfunction in nonalcoholic fatty liver disease by regulating SERCA pathway," *Journal of Translational Medicine*, vol. 17, no. 1, p. 277, 2019.

[15] N. Zhang, J. Tao, L. Gao et al., "Liraglutide attenuates non-alcoholic fatty liver disease by modulating gut microbiota in rats administered a high-fat diet," *BioMed Research International*, vol. 2020, Article ID 2947549, 10 pages, 2020.

[16] P. Rada, A. Gonzalez-Rodriguez, C. Garcia-Monzon, and A. M. Valverde, "Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?" *Cell Death & Disease*, vol. 11, no. 9, p. 802, 2020.